Search Results for: collaboration

OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22:15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the

Read more

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and

Read more

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

Dr. Zbigniew Zasłona, a biologist and scientist with impressive achievements in the area of pulmonary diseases (at Trinity College Dublin since 2015) has joined the research team of OncoArendi Therapeutics S.A. Prior to his collaboration with

Read more

Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's

Read more

Molecure’s success in development of the mRNA discovery platform

- Molecure confirms that small molecules designed to target mRNA inhibit translation of the encoded protein relevant in cancer - Proof-of-Concept has been demonstrated in a cell assay - Reaching the PoC stage for the first

Read more

Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum

Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseases Completed successful Secondary Public Offering (SPO) of gross proceeds of

Read more

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

Closing of equity offering of 2,776,000 series H shares by private placement, offered within the authorised capital, at an issue price of PLN 18 per share Series H shares were subscribed for by 35 investors, new

Read more

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

The agreement with Simbec-Orion includes organizing and fully executing a proof-of-concept Phase II clinical trial in patients with pulmonary sarcoidosis. The Phase II proof-of-concept study of OATD-01 will be conducted as multi-center and international clinical trial

Read more

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compounds First patient dosed in Phase I trial with OATD-02, a novel, first in class dual arginase inhibitor for the treatment of cancer Lead

Read more
This site is registered on wpml.org as a development site.